Ruxolitinib (INCB18424) is a potent, selective, ATP-competitive JAK1/2 inhibitor. It affects the JAK/STAT signaling pathway by binding to the JAK ATP-binding site and blocking STAT phosphorylation, inhibiting cell proliferation and inflammation, and promoting apoptosis.
Ruxolitinib (INCB18424) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Ruxolitinib (INCB18424) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.